RCM Technologies, Inc. (RCMT) - 10-Q Summary
Business Context and Reporting Period
This report covers the unaudited financial results for the thirteen and thirty-nine weeks ended September 27, 2025. RCM Technologies, Inc. provides engineering, life sciences, data, and solutions services, as well as specialty healthcare staffing. The company operates under a 52/53-week fiscal calendar; the current fiscal year (2025) is a 53-week year.
Key Financial Metrics
| Metric | 13 Weeks Ended Sept 27, 2025 | 39 Weeks Ended Sept 27, 2025 |
|---|---|---|
| Revenue | $70.3 million | $232.9 million |
| Gross Profit | $19.4 million (27.6% margin) | $63.7 million (27.3% margin) |
| Operating Income | $3.9 million (5.6% margin) | $17.1 million (7.3% margin) |
| Net Income | $2.3 million | $10.2 million |
| Diluted EPS | $0.30 | $1.34 |
| Cash and Equivalents | $1.3 million | $1.3 million (Ending Balance) |
| Debt (Line of Credit) | $31.5 million | $31.5 million (Ending Balance) |
| Working Capital | $46.9 million | $46.9 million |
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 16.4% year-over-year for the quarter ($9.9M increase) and 15.6% for the year-to-date ($31.4M increase). Growth was driven by the Engineering segment (+30.0% Q/Q) and Specialty Health Care segment (+13.0% Q/Q), partially offset by a decline in Life Sciences, Data and Solutions (-8.0% Q/Q).
- Profitability: While revenue grew, gross margins compressed slightly due to a mix shift toward lower-margin Engineering EPC projects and Aerospace work. Operating income decreased 10.2% for the quarter ($3.9M vs $4.4M) primarily due to increased Selling, General, and Administrative (SG&A) expenses, though it increased 6.8% year-to-date.
- Cost Structure: SG&A expenses rose 14.7% for the quarter, driven by investments in sales and recruiting infrastructure for the new school year and increased corporate medical costs.
- Cash Flow: Net cash provided by operating activities was $7.5 million for the 39-week period, a slight decrease from $7.8 million in the prior year. Cash decreased by $3.4 million during the period, largely due to financing activities (share repurchases and debt repayment).
Guidance, Outlook, and Risks
- Outlook: Management anticipates continued demand for outsourcing in AI, Quality by Design (QbD), and process automation. The company expects to maintain compliance with financial covenants and believes it has sufficient liquidity for the next 12 months.
- Capital Allocation: The company continues its share repurchase program, having purchased 301,640 shares for $5.1 million in the first three quarters of 2025. Approximately $37.1 million remains available under the current authorization.
- Risks: Key risks include customer concentration (two customers accounted for 32.8% of YTD revenue), credit and collection risks, and exposure to workers' compensation and healthcare insurance claims. The company also faces risks related to foreign currency fluctuations and potential changes in healthcare regulations.
- Unusual Items: The company recognized a $0.4 million accrual for asserted legal claims. There were no material impairments of goodwill or intangible assets.
Investor Verification Checklist
- Customer Concentration: Verify the stability of the two major clients in the Specialty Health Care segment representing over 30% of YTD revenue.
- Margin Trends: Monitor the Engineering segment's gross margin compression as EPC project mix increases.
- Liquidity Position: Assess the impact of the $31.5 million line of credit draw and the $1.3 million cash balance on daily operations, given the company's reliance on the credit facility for liquidity.
- Share Repurchases: Confirm the pace of the $50 million buyback program and its impact on cash reserves.
- Legal Contingencies: Review the $0.4 million accrued liability for legal claims and potential exposure beyond this amount.